Arrowstreet Capital, Limited Partnership Cytom X Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$6.6 - $9.0 $1.89 Million - $2.57 Million	-286,039 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$6.47 - $7.9 $1.14 Million - $1.39 Million	175,693 Added 159.22%	286,039 $1.87 Million
Q3 2020 Nov 12, 2020	BUY	$6.55 - $8.83 $179,430 - $241,889	27,394 Added 33.02%	110,346 $734,000
Q2 2020 Aug 12, 2020	BUY	$7.4 - $14.64 $613,844 - $1.21 Million	82,952 New	82,952 $691,000
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $2.08 Million - $3.05 Million	-163,887 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $1.58 Million - $2.32 Million	87,796 Added 115.38%	163,887 $3.03 Million
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $1.07 Million - $1.49 Million	50,268 Added 194.66%	76,091 $1.74 Million
Q1 2018 May 14, 2018	BUY	$21.76 - $34.22 $561,908 - $883,663	25,823 New	25,823 $735,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.